Everything below concerns analytical methods. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
=== 1999–2005: Film debut and breakthrough === In 1999, Larter made her film debut in the coming-of-age dramedy Varsity Blues, which reunited her with Dawson's Creek star James Van Der Beek and close friend Amy Smart. Smart had persuaded Larter to audition for the movie, in which Larter played Darcy Sears, a love interest for Lance Harbor (Paul Walker). Varsity Blues drew a domestic box office gross of $53 million. Also in 1999, she made supporting appearances in the teen comedies Giving It Up and Drive Me Crazy, and starred in the remake House on Haunted Hill which was made for around $20 million. The horror film about a group of strangers invited to a party at an abandoned asylum, was panned by critics, but grossed $15 million on its opening weekend eventually earning over $40 million overall. Larter starred as Clear Rivers, one of the main characters in the teen supernatural horror film Final Destination (2000). Also starring Devon Sawa from British Columbia, and Kerr Smith, the movie's premise is several teenagers survive a plane crash but are stalked and killed by death itself. Final Destination made $112 million by the end of its theatrical run. In 2001, she appeared in the comedy Legally Blonde with Reese Witherspoon. Larter played Brooke Taylor Windham, a widow accused of her husband Hayworth's murder. The film held the top spot with $20 million in its opening weekend and ended up grossing $141 million worldwide. With $96 million of its total gross deriving from domestic markets, Legally Blonde is her highest-grossing film domestically.
== Tissue distribution == Type III collagen is found as a major structural component in hollow organs such as large blood vessels, uterus and bowel. It is also found in many other tissues together with type I collagen.
== Materials and construction == A common hand tool, the crowbar is typically made of medium-carbon steel, possibly hardened on its ends. Commonly crowbars are forged from long steel stock, either hexagonal or sometimes cylindrical. Alternative designs may be forged with a rounded I-shaped cross-section shaft. Versions using relatively wide flat steel bar are often referred to as "utility" or "flat bars".
Sources: en.wikipedia.org
== Rates, mechanisms, and energies == Redox reactions can occur slowly, as in the formation of rust, or rapidly, as in the case of burning fuel. Electron transfer reactions are generally fast, occurring within the time of mixing. The mechanisms of atom-transfer reactions are highly variable because many kinds of atoms can be transferred, and such reactions can involve several steps. Electron-transfer reactions, by contrast, proceed by two distinct pathways. In inner-sphere transfer, the two reactants share a bridging ligand through which the electron passes; in outer-sphere transfer, the electron moves between reactants whose coordination shells remain intact. Henry Taube received the 1983 Nobel Prize in Chemistry for distinguishing these pathways through experiments on metal complexes. The rate of an outer-sphere electron transfer is described by Marcus theory, developed by Rudolph A. Marcus. The theory expresses the activation energy in terms of two quantities: the standard free-energy change of the reaction and the reorganization energy, the energy needed to distort the reactants and the surrounding solvent into the configuration of the products before the electron moves. It predicts an "inverted region", in which the rate falls once the driving force exceeds the reorganization energy. Marcus received the 1992 Nobel Prize in Chemistry for the theory. Analysis of bond energies and ionization energies in water allows calculation of the thermodynamic aspects of redox reactions.
== Sequence and protein expression == Mutations in the Shine–Dalgarno sequence can reduce or increase translation in prokaryotes. This change is due to a reduced or increased mRNA-ribosome pairing efficiency, as evidenced by the fact that compensatory mutations in the 3'-terminal 16S rRNA sequence can restore translation.
After nearly a decade's absence, Dunkin' Donuts returned to the state of Minnesota in 2014; a new shop opened inside the Kahler Grand Hotel in Rochester. In the United States, Dunkin' is sometimes paired with Baskin-Robbins ice cream in a single multibranded store. While such locations usually maintain separate counters for each chain (much like co-branded Wendy's–Tim Hortons locations in Canada), depending on business that day, both chains' products can be bought at a single counter (typically Dunkin' Donuts'). The practice of single-counter service is similar to that of multibranded Yum! Brands stores such as KFC–Taco Bell, which share a single kitchen and cashier line. As of February 9, 2017, all Dunkin' locations are franchisee owned and operated. In addition to its stand-alone shops, Dunkin' shops can be found within many gas stations, supermarkets, mall and airport food courts, and Walmart stores. In July 2013, Dunkin' Donuts opened its 500th restaurant in New York City. This location is combined with a Baskin-Robbins. On July 30, 2020, Dunkin' Brands announced it would permanently close 800 stores in the US by the end of the year because of a 20 percent drop in sales in the second quarter during the COVID-19 pandemic, 450 of which are part of the previously announced closing of locations within Speedway gas stations. As of 2019, 40 Dunkin' Donuts shops in the United States were certified fully kosher, in addition to one that sells both kosher-certified and non-kosher products.
Under the Reagan administration, Project Socrates determined that the Soviet Union addressed the acquisition of science and technology in a manner radically different to the United States. The US prioritized indigenous research and development in both the public and private sectors. In contrast, the USSR placed greater emphasis on acquiring foreign technology, which it did through both covert and overt means. However, centralized state planning kept Soviet technological development greatly inflexible. This was exploited by the US to undermine the strength of the Soviet Union and thus foster its reform.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.